Jay Kakadiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jay Kakadiya has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Dhairya A. Lakhani
Department of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA
17 shared publications - Ajay Malhotra
Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT 06520, USA
12 shared publications - Marco Colasurdo
Department of Interventional Radiology (M.C.), Oregon Health and Science University, Portland
12 shared publications - Adam Andrew Dmytriw
Nuffield Department of Surgical Sciences, Medical Sciences Division, University of Oxford, Oxford, United Kingdom
10 shared publications - Hamza Adel Salim
Department of Neuroradiology, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA
10 shared publications - Huanwen Chen
Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA
9 shared publications
Latest Publications
- 7 November 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (11) , 705
GLP-1 receptor agonist use in patients with minor stroke is associated with lower risk of post-stroke dementia
- 7 November 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (11) , 705
GLP-1 receptor agonist use in patients with minor stroke is associated with lower risk of post-stroke dementia
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (11) , 3431-3437
Transcarotid Artery Revascularization Versus Carotid Artery Stenting for Asymptomatic Carotid Stenosis
BACKGROUND: The CREST-2 trial (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial) demonstrated superiority of carotid artery stenting (CAS) over intensive medical management for asymptomatic carotid stenosis, but it did not evaluate transcarotid artery revascularization (TCAR). Herein, we compared ischemic stroke outcomes between TCAR and CAS among patients with asymptomatic carotid stenosis in contemporary real-world practice. METHODS: We identified adults with asymptomatic carotid stenosis undergoing TCAR versus CAS using the 2016 to 2024 TriNetX database, which is a multicenter federated database of electronic health records. Propensity score matching was performed for demographics, laboratory values, risk factors, comorbidities, and medications. The primary outcome was ischemic stroke within 4 years. RESULTS: Among 7303 identified patients, 2207 patients remained in each group after matching. TCAR did not demonstrate a significantly different stroke risk compared with CAS (hazard ratio, 0.68 [95% CI, 0.44–1.06]). The absolute risk difference was numerically but nonsignificantly lower for patients with TCAR throughout the follow-up period, progressively widening over time: 0.35% at 6 months (0.61% versus 0.96%; P =0.18) to 1.55% at 4 years (3.26% versus 4.81%; P =0.086). CONCLUSIONS: TCAR did not significantly lower stroke risk compared with CAS for asymptomatic carotid stenosis. Although nonsignificant trends towards lower stroke risk were observed for TCAR, the widening of absolute risk differences over time suggests residual confounding rather than potential procedural benefit.
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (11) , 3431-3437
Transcarotid Artery Revascularization Versus Carotid Artery Stenting for Asymptomatic Carotid Stenosis
BACKGROUND: The CREST-2 trial (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial) demonstrated superiority of carotid artery stenting (CAS) over intensive medical management for asymptomatic carotid stenosis, but it did not evaluate transcarotid artery revascularization (TCAR). Herein, we compared ischemic stroke outcomes between TCAR and CAS among patients with asymptomatic carotid stenosis in contemporary real-world practice. METHODS: We identified adults with asymptomatic carotid stenosis undergoing TCAR versus CAS using the 2016 to 2024 TriNetX database, which is a multicenter federated database of electronic health records. Propensity score matching was performed for demographics, laboratory values, risk factors, comorbidities, and medications. The primary outcome was ischemic stroke within 4 years. RESULTS: Among 7303 identified patients, 2207 patients remained in each group after matching. TCAR did not demonstrate a significantly different stroke risk compared with CAS (hazard ratio, 0.68 [95% CI, 0.44–1.06]). The absolute risk difference was numerically but nonsignificantly lower for patients with TCAR throughout the follow-up period, progressively widening over time: 0.35% at 6 months (0.61% versus 0.96%; P =0.18) to 1.55% at 4 years (3.26% versus 4.81%; P =0.086). CONCLUSIONS: TCAR did not significantly lower stroke risk compared with CAS for asymptomatic carotid stenosis. Although nonsignificant trends towards lower stroke risk were observed for TCAR, the widening of absolute risk differences over time suggests residual confounding rather than potential procedural benefit.
- 20 October 2026
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- p. ajnr.A9690
ASFNR Clinical State of Practice Statement on Imaging of Chronic Subdural Hematoma
- 20 October 2026
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- p. ajnr.A9690
ASFNR Clinical State of Practice Statement on Imaging of Chronic Subdural Hematoma
- Open Access
- 3 October 2026
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (12) , 6331-6335
Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome (CANVAS): A case report of RFC1-associated disease
- 3 October 2026
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (12) , 6331-6335
Open AccessCerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome (CANVAS): A case report of RFC1-associated disease
- 18 September 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Anxiety and mood disorders are associated with greater healthcare and procedural utilization in idiopathic intracranial hypertension
Background and purpose: Anxiety and mood disorders (AMD) are common in idiopathic intracranial hypertension (IIH), but their association with procedural treatment and healthcare utilization is unclear. We evaluated utilization among patients with AMD documented before or shortly after IIH. Methods: Using the TriNetX US Collaborative Network, we identified adults diagnosed with IIH on or after January 1, 2016. The primary analysis compared patients with AMD documented on or before IIH with those without AMD; the sensitivity analysis compared patients with a first AMD diagnosis within 1 month after IIH with those without AMD before or during that month. Each analysis used separate 1:1 propensity-score matching. 5-year outcomes were assessed using Kaplan-Meier methods and Cox regression. Results: The primary analysis included 38 117 matched patients per group. At 5 years, patients with AMD had higher rates of cerebrospinal fluid shunting (5.86% vs 4.62%; HR 1.168), transverse venous sinus stenting (1.40% vs 1.09%; HR 1.236), either procedure (7.12% vs 5.61%; HR 1.178), inpatient admission (45.63% vs 36.88%; HR 1.214), and emergency department visits (56.57% vs 42.57%; HR 1.519), but lower mortality (7.70% vs 9.67%; HR 0.725). The sensitivity analysis included 8949 matched patients per group and showed the same pattern among patients with AMD newly diagnosed within 1 month after IIH. Conclusions: AMD documented before or shortly after IIH was associated with greater procedural and healthcare utilization. These observational findings describe patterns of care but do not establish that AMD causes greater IIH severity or procedural need.
- 18 September 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Anxiety and mood disorders are associated with greater healthcare and procedural utilization in idiopathic intracranial hypertension
Background and purpose: Anxiety and mood disorders (AMD) are common in idiopathic intracranial hypertension (IIH), but their association with procedural treatment and healthcare utilization is unclear. We evaluated utilization among patients with AMD documented before or shortly after IIH. Methods: Using the TriNetX US Collaborative Network, we identified adults diagnosed with IIH on or after January 1, 2016. The primary analysis compared patients with AMD documented on or before IIH with those without AMD; the sensitivity analysis compared patients with a first AMD diagnosis within 1 month after IIH with those without AMD before or during that month. Each analysis used separate 1:1 propensity-score matching. 5-year outcomes were assessed using Kaplan-Meier methods and Cox regression. Results: The primary analysis included 38 117 matched patients per group. At 5 years, patients with AMD had higher rates of cerebrospinal fluid shunting (5.86% vs 4.62%; HR 1.168), transverse venous sinus stenting (1.40% vs 1.09%; HR 1.236), either procedure (7.12% vs 5.61%; HR 1.178), inpatient admission (45.63% vs 36.88%; HR 1.214), and emergency department visits (56.57% vs 42.57%; HR 1.519), but lower mortality (7.70% vs 9.67%; HR 0.725). The sensitivity analysis included 8949 matched patients per group and showed the same pattern among patients with AMD newly diagnosed within 1 month after IIH. Conclusions: AMD documented before or shortly after IIH was associated with greater procedural and healthcare utilization. These observational findings describe patterns of care but do not establish that AMD causes greater IIH severity or procedural need.
- 14 August 2026
- Published by Wolters Kluwer Health in Neurosurgery
Glucagon-Like Peptide-1 Receptor Agonists for Patients with Conservatively Managed Nontraumatic Subdural Hematoma
BACKGROUND AND OBJECTIVES: Medical management options for nontraumatic subdural hematoma (SDH) remain limited, with only atorvastatin demonstrating benefit in a single phase 2 randomized clinical trial and mixed evidence for dexamethasone. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may benefit SDH outcomes. The objective of this study was to evaluate the association between GLP-1 RA use and rescue surgery rates and mortality in patients with medically managed nontraumatic SDH. METHODS: We conducted a retrospective cohort study using the TriNetX database from 2016 to 2025, including adults with SDH who were managed conservatively without surgical evacuation or middle meningeal artery embolization. Patients prescribed GLP-1 RAs were compared with nonusers. After propensity matching, rescue surgical evacuation, all-cause mortality at 1 year, and GLP-1 RA–associated adverse events were analyzed. RESULTS: A total of 134 901 patients with conservatively managed nontraumatic SDH were identified, of whom 1470 (1.1%) were GLP-1 RA users. After propensity score matching, 2922 patients remained, with 1461 in each group. At 1 year, GLP-1 RA users experienced significantly lower rates of rescue surgery (2.23% vs 3.51%; P = .046), culminating in an overall 38% reduction in relative hazard. All-cause mortality was also significantly lower for GLP-1 RA users at 1 year (16.1% vs 23.7%, P < .001), reflecting a 33% reduction in hazards. GLP-1 RA users did not experience different rates of adverse events, such as pancreatitis, gallbladder disease, or ileus/bowel obstruction (all P > .05). CONCLUSION: Among patients with medically managed nontraumatic SDH, GLP-1 RA use was associated with significantly lower rates of rescue surgery and all-cause mortality without significantly increased risk of common GLP-1 RA–related complications.
- 14 August 2026
- Published by Wolters Kluwer Health in Neurosurgery
Glucagon-Like Peptide-1 Receptor Agonists for Patients with Conservatively Managed Nontraumatic Subdural Hematoma
BACKGROUND AND OBJECTIVES: Medical management options for nontraumatic subdural hematoma (SDH) remain limited, with only atorvastatin demonstrating benefit in a single phase 2 randomized clinical trial and mixed evidence for dexamethasone. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may benefit SDH outcomes. The objective of this study was to evaluate the association between GLP-1 RA use and rescue surgery rates and mortality in patients with medically managed nontraumatic SDH. METHODS: We conducted a retrospective cohort study using the TriNetX database from 2016 to 2025, including adults with SDH who were managed conservatively without surgical evacuation or middle meningeal artery embolization. Patients prescribed GLP-1 RAs were compared with nonusers. After propensity matching, rescue surgical evacuation, all-cause mortality at 1 year, and GLP-1 RA–associated adverse events were analyzed. RESULTS: A total of 134 901 patients with conservatively managed nontraumatic SDH were identified, of whom 1470 (1.1%) were GLP-1 RA users. After propensity score matching, 2922 patients remained, with 1461 in each group. At 1 year, GLP-1 RA users experienced significantly lower rates of rescue surgery (2.23% vs 3.51%; P = .046), culminating in an overall 38% reduction in relative hazard. All-cause mortality was also significantly lower for GLP-1 RA users at 1 year (16.1% vs 23.7%, P < .001), reflecting a 33% reduction in hazards. GLP-1 RA users did not experience different rates of adverse events, such as pancreatitis, gallbladder disease, or ileus/bowel obstruction (all P > .05). CONCLUSION: Among patients with medically managed nontraumatic SDH, GLP-1 RA use was associated with significantly lower rates of rescue surgery and all-cause mortality without significantly increased risk of common GLP-1 RA–related complications.
- 13 August 2026
- Published by Wolters Kluwer Health in Neurosurgery
Carotid Artery Stenting Versus Carotid Endarterectomy for Asymptomatic Carotid Stenosis: A Propensity Score–Matched Real-World Analysis
BACKGROUND AND OBJECTIVES: Carotid artery stenting (CAS) and carotid endarterectomy (CEA) are established revascularization strategies for carotid stenosis, yet evidence comparing them in asymptomatic populations remains limited. The Carotid Revascularization Endarterectomy versus Stenting Trial-2 used a parallel-arm design and did not provide a direct head-to-head comparison of CAS vs CEA. This study evaluates real-world long-term outcomes of CAS compared directly with those of CEA in asymptomatic carotid stenosis. METHODS: Adults with asymptomatic carotid stenosis undergoing CAS or CEA between January 2016 and December 2024 were identified from the TriNetX US Collaborative Network. Patients with previous ischemic stroke, TIA, hemorrhage, or posterior-circulation stenosis were excluded. Propensity score matching (1:1) on demographics, comorbidities, and baseline antithrombotic medications yielded 5415 patients per cohort. Primary outcomes were all-cause mortality and ischemic stroke at 5 years; secondary outcomes included intraparenchymal hemorrhage and major bleeding. Kaplan–Meier analyses with log-rank testing and Cox proportional hazards models were used, with outcomes assessed at 6 months, 1, 3, and 5 years. RESULTS: Ischemic stroke occurred in 10.0% of CAS vs 9.8% of CEA patients (cumulative probability 15.85% vs 14.07%; hazard ratio [HR] 1.179, 95% CI 1.045-1.329, P = .007). All-cause mortality was higher after CAS (21.70% vs 18.69%; HR 1.212, 95% CI 1.084-1.355, P = .001). Intraparenchymal hemorrhage was more frequent after CAS (2.11% vs 1.30%; HR 1.940, 95% CI 1.327-2.835, P < .001). Major bleeding rates were comparable (12.10% vs 11.88%; HR 1.130, P = .071). All standardized differences were <0.10 postmatching. CONCLUSION: In real-world practice, CAS for asymptomatic carotid stenosis was associated with modestly higher ischemic stroke, mortality, and intraparenchymal hemorrhage compared with CEA over 5 years, suggesting an association favoring CEA. Prospective studies are needed to establish definitive causal relationships.
- 13 August 2026
- Published by Wolters Kluwer Health in Neurosurgery
Carotid Artery Stenting Versus Carotid Endarterectomy for Asymptomatic Carotid Stenosis: A Propensity Score–Matched Real-World Analysis
BACKGROUND AND OBJECTIVES: Carotid artery stenting (CAS) and carotid endarterectomy (CEA) are established revascularization strategies for carotid stenosis, yet evidence comparing them in asymptomatic populations remains limited. The Carotid Revascularization Endarterectomy versus Stenting Trial-2 used a parallel-arm design and did not provide a direct head-to-head comparison of CAS vs CEA. This study evaluates real-world long-term outcomes of CAS compared directly with those of CEA in asymptomatic carotid stenosis. METHODS: Adults with asymptomatic carotid stenosis undergoing CAS or CEA between January 2016 and December 2024 were identified from the TriNetX US Collaborative Network. Patients with previous ischemic stroke, TIA, hemorrhage, or posterior-circulation stenosis were excluded. Propensity score matching (1:1) on demographics, comorbidities, and baseline antithrombotic medications yielded 5415 patients per cohort. Primary outcomes were all-cause mortality and ischemic stroke at 5 years; secondary outcomes included intraparenchymal hemorrhage and major bleeding. Kaplan–Meier analyses with log-rank testing and Cox proportional hazards models were used, with outcomes assessed at 6 months, 1, 3, and 5 years. RESULTS: Ischemic stroke occurred in 10.0% of CAS vs 9.8% of CEA patients (cumulative probability 15.85% vs 14.07%; hazard ratio [HR] 1.179, 95% CI 1.045-1.329, P = .007). All-cause mortality was higher after CAS (21.70% vs 18.69%; HR 1.212, 95% CI 1.084-1.355, P = .001). Intraparenchymal hemorrhage was more frequent after CAS (2.11% vs 1.30%; HR 1.940, 95% CI 1.327-2.835, P < .001). Major bleeding rates were comparable (12.10% vs 11.88%; HR 1.130, P = .071). All standardized differences were <0.10 postmatching. CONCLUSION: In real-world practice, CAS for asymptomatic carotid stenosis was associated with modestly higher ischemic stroke, mortality, and intraparenchymal hemorrhage compared with CEA over 5 years, suggesting an association favoring CEA. Prospective studies are needed to establish definitive causal relationships.
- 13 July 2026
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 362, 112285
Resting-state functional connectivity alterations in adult ADHD: A systematic review of rs-fMRI studies
- 13 July 2026
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 362, 112285
Resting-state functional connectivity alterations in adult ADHD: A systematic review of rs-fMRI studies
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (7) , 1979-1990
GLP-1 Receptor Agonist Use Is Associated With Lower Risk of Intracranial Aneurysm Rupture and Rupture Severity
BACKGROUND: Unruptured intracranial aneurysms (UIAs) affect up to 5% of the population, and rupture can lead to devastating subarachnoid hemorrhage. GLP-1RAs (glucagon-like peptide-1 receptor agonists) have anti-inflammatory and vasculoprotective effects, but their impact on aneurysm stability and subarachnoid hemorrhage outcomes is unexplored. This study evaluated whether GLP-1RA use is associated with reduced rupture risk and attenuated severity in the event of a rupture. METHODS: We conducted a retrospective cohort study using the TriNetX US Collaborative Network (2016–2024). Cohort 1 included patients with newly diagnosed, untreated UIA; cohort 2 included those who suffered aneurysm rupture. GLP-1RA exposure was defined as use before or within 3 months of UIA diagnosis (cohort 1) or before rupture (cohort 2). The primary outcome was aneurysm rupture risk in cohort 1. Secondary outcomes include presentation severity, vasospasm, and mortality in cohort 2. Propensity score matching balanced demographics, comorbidities, and medications. RESULTS: After propensity score match, cohort 1 of patients with untreated UIA included 8088 GLP-1RA users and 8088 nonusers. GLP-1RA use was associated with significantly lower probabilities of aneurysm rupture at 1-year (0.65% versus 1.51%; P P P P P P =0.002), as well as numerically lower rates of 30-day mortality (9.4% versus 14.1%; P =0.21). CONCLUSIONS: For patients with untreated UIA, GLP-1RA use was associated with a 48% reduction in aneurysm rupture risk and, among those who suffered aneurysm rupture, milder clinical and radiographic severity. These findings suggest possible neuroprotective and vascular stabilizing effects of GLP-1RAs for patients with UIA.
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (7) , 1979-1990
GLP-1 Receptor Agonist Use Is Associated With Lower Risk of Intracranial Aneurysm Rupture and Rupture Severity
BACKGROUND: Unruptured intracranial aneurysms (UIAs) affect up to 5% of the population, and rupture can lead to devastating subarachnoid hemorrhage. GLP-1RAs (glucagon-like peptide-1 receptor agonists) have anti-inflammatory and vasculoprotective effects, but their impact on aneurysm stability and subarachnoid hemorrhage outcomes is unexplored. This study evaluated whether GLP-1RA use is associated with reduced rupture risk and attenuated severity in the event of a rupture. METHODS: We conducted a retrospective cohort study using the TriNetX US Collaborative Network (2016–2024). Cohort 1 included patients with newly diagnosed, untreated UIA; cohort 2 included those who suffered aneurysm rupture. GLP-1RA exposure was defined as use before or within 3 months of UIA diagnosis (cohort 1) or before rupture (cohort 2). The primary outcome was aneurysm rupture risk in cohort 1. Secondary outcomes include presentation severity, vasospasm, and mortality in cohort 2. Propensity score matching balanced demographics, comorbidities, and medications. RESULTS: After propensity score match, cohort 1 of patients with untreated UIA included 8088 GLP-1RA users and 8088 nonusers. GLP-1RA use was associated with significantly lower probabilities of aneurysm rupture at 1-year (0.65% versus 1.51%; P P P P P P =0.002), as well as numerically lower rates of 30-day mortality (9.4% versus 14.1%; P =0.21). CONCLUSIONS: For patients with untreated UIA, GLP-1RA use was associated with a 48% reduction in aneurysm rupture risk and, among those who suffered aneurysm rupture, milder clinical and radiographic severity. These findings suggest possible neuroprotective and vascular stabilizing effects of GLP-1RAs for patients with UIA.
- 2 June 2026
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- p. ajnr.A9443
Glucagon-Like Peptide-1 Receptor Agonist Exposure and Long-Term Outcomes in Patients with Asymptomatic Carotid Stenosis: A Propensity Score–Matched Real-World Analysis
Asymptomatic carotid stenosis is a prevalent manifestation of atherosclerotic disease and, despite contemporary guideline-directed medical therapy, remains associated with downstream cerebrovascular events and mortality. Given the vascular and cardiometabolic benefits of glucagon-like peptide-1 receptor agonists (GLP-1As), we evaluated whether GLP-1A exposure is associated with lower long-term event rates in patients with asymptomatic carotid stenosis. This retrospective study used the TriNetX US Collaborative Network. Adults (≥18 years) with carotid stenosis (January 1, 2016-September 30, 2025) were included; patients with prior/baseline cerebrovascular events and those undergoing carotid revascularization within 6 months were excluded to operationalize an asymptomatic cohort. GLP-1A exposure was defined as any GLP-1A use within 6 months following carotid stenosis diagnosis; non-exposed patients served as comparators. Cohorts were propensity score-matched 1:1, and outcomes were assessed using Kaplan-Meier and Cox proportional hazards models. After matching, 30,332 patients were included in each cohort. GLP-1A exposure was associated with lower hazards of ischemic stroke (HR 0.63/0.71/0.73 at 1/3/5 years; 5-year cumulative event probability 5.55% vs 6.85%), hemorrhagic stroke (HR 0.63/0.69/0.74; 2.04% vs 2.35%), large-vessel occlusion stroke (HR 0.70/0.77/0.81; 2.04% vs 2.27%), and all-cause mortality (HR 0.42/0.58/0.64; 17.11% vs 21.49%). The composite of ischemic stroke or mortality was also lower (HR 0.48/0.61/0.66; 20.88% vs 25.85% at 5 years) in the GLP-1A exposed cohort. In large real-world cohort with asymptomatic carotid stenosis, GLP-1A exposure was associated with lower hazards of stroke subtypes, large-vessel occlusion stroke, and mortality across 1-5 years. These observational findings warrant prospective validation to clarify causality and optimal integration into contemporary medical management.
- 2 June 2026
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- p. ajnr.A9443
Glucagon-Like Peptide-1 Receptor Agonist Exposure and Long-Term Outcomes in Patients with Asymptomatic Carotid Stenosis: A Propensity Score–Matched Real-World Analysis
Asymptomatic carotid stenosis is a prevalent manifestation of atherosclerotic disease and, despite contemporary guideline-directed medical therapy, remains associated with downstream cerebrovascular events and mortality. Given the vascular and cardiometabolic benefits of glucagon-like peptide-1 receptor agonists (GLP-1As), we evaluated whether GLP-1A exposure is associated with lower long-term event rates in patients with asymptomatic carotid stenosis. This retrospective study used the TriNetX US Collaborative Network. Adults (≥18 years) with carotid stenosis (January 1, 2016-September 30, 2025) were included; patients with prior/baseline cerebrovascular events and those undergoing carotid revascularization within 6 months were excluded to operationalize an asymptomatic cohort. GLP-1A exposure was defined as any GLP-1A use within 6 months following carotid stenosis diagnosis; non-exposed patients served as comparators. Cohorts were propensity score-matched 1:1, and outcomes were assessed using Kaplan-Meier and Cox proportional hazards models. After matching, 30,332 patients were included in each cohort. GLP-1A exposure was associated with lower hazards of ischemic stroke (HR 0.63/0.71/0.73 at 1/3/5 years; 5-year cumulative event probability 5.55% vs 6.85%), hemorrhagic stroke (HR 0.63/0.69/0.74; 2.04% vs 2.35%), large-vessel occlusion stroke (HR 0.70/0.77/0.81; 2.04% vs 2.27%), and all-cause mortality (HR 0.42/0.58/0.64; 17.11% vs 21.49%). The composite of ischemic stroke or mortality was also lower (HR 0.48/0.61/0.66; 20.88% vs 25.85% at 5 years) in the GLP-1A exposed cohort. In large real-world cohort with asymptomatic carotid stenosis, GLP-1A exposure was associated with lower hazards of stroke subtypes, large-vessel occlusion stroke, and mortality across 1-5 years. These observational findings warrant prospective validation to clarify causality and optimal integration into contemporary medical management.